Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 72 Matches

Tafenoquine

Model Files Publication

Brand Name(s) include: Arakoda, Krintafel

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 3) Note: Kp scalar used
Route of Elimination	Undefined liver intrinsic clearance
Perpetrator DDI	CYP2C9 Inhibitor CYP3A4 Inhibitor
Validation	Four clinical studies describing single and multiple dose exposure of tafenoquine were used to verify the PBPK model, although some of these provided PK profiles and no PK parameters and vice versa. Of the clinical studies describing PK parameters, the model recovered 100% of the observed PK parameters within 1.5-fold (66% within 0.8-1.25-fold) and hence the model is considered predictive.
Limitations	Tafenoquine is administered with food to increase its exposure and minimize gastrointestinal side effects. The PBPK model was therefore developed to recover the PK of tafenoquine in the fed state. It should be noted that in the absence of information defining the fm of drug metabolizing enzymes, an undefined liver intrinsic clearance is used in the model and hence the model is not able to simulate the liability of tafenoquine as a victim of DDIs.

Search Score: 1

Adefovir_V15R1_USFDA_20170810

Model Files Publication

http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Adefovir compound in healthy volunteers. Hsueh et al evaluating the effect of renal impairment on PK of OAT substrates. 30/07/2019: The Adefovir PBPK model was submitted with the setting as Hepatocyte Clearance input in the WOMC option. To allow DDI simulations the file should be set up in the Enzyme Kinetics option by moving the Hepatocyte clearance value into the Additional Clearance (Liver) subtab under the Enzyme Kinetics section.

Search Score: 1

Ertugliflozin_V15R1_Pfizer_20220726

Model Files Publication

Ertugliflozin compound file, UGT1A9 and UGT2B4/7 substrate. Model developed and verified using ADME, IV PK and SD/MD clinical data. Simulated DDI with UGT inhibitor mefenamic acid. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.12581

Search Score: 1

Famotidine_V15R1_USFDA_20170810

Model Files Publication

http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Famotidine compound file in healthy volunteers. Evaluation of the effect of renal impairment on the PK of OAT substrates. NOTE: MW is slightly different between model file and Table 1.

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Tafenoquine

The model at-a-glance

Adefovir_V15R1_USFDA_20170810

Ertugliflozin_V15R1_Pfizer_20220726

Famotidine_V15R1_USFDA_20170810

Your Privacy